The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA) has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia (JMML). Azacitidine...
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of certain adult...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult...
The FDA has approved a radioactive compound and companion diagnostic test for patients with advanced prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for adult...
The FDA approved pembrolizumab for certain patients with advanced endometrial cancer with DNA repair defects The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with advanced...
The FDA approved nivolumab and relatlimab-rmbw (Opdualag) for some patients with advanced melanoma The U.S. Food and Drug Administration (FDA) has approved a combination of the checkpoint inhibitors nivolumab and relatlimab-rmbw (Opdualag) for...
The FDA approved olaparib for patients with breast cancer who have inherited BRCA mutations and have received prior neoadjuvant or adjuvant immunotherapy The U.S. Food and Drug Administration (FDA) has approved the PARP inhibitor...
The FDA approved nivolumab in combination with chemotherapy for use before surgery in certain patients with non-small cell lung cancer The U.S. Food and Drug Administration (FDA) has approved the immune checkpoint inhibitor...
The FDA recently approved the second cellular immunotherapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved ciltacabtagene autoleucel (Carvykti) to treat adult patients with relapsed...
The FDA approved the targeted immunotherapy tebentafusp-tebn for certain adult patients with uveal melanoma. The U.S. Food and Drug Administration (FDA) has approved tebentafusp-tebn (Kimmtrak), a fusion protein that acts as an immunotherapy, for...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 50,000 members worldwide drive progress against cancer.
Donate Now